SG11201504340YA - Treatment of diseases of endothelial dysfunction and inflammation - Google Patents

Treatment of diseases of endothelial dysfunction and inflammation

Info

Publication number
SG11201504340YA
SG11201504340YA SG11201504340YA SG11201504340YA SG11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA
Authority
SG
Singapore
Prior art keywords
inflammation
diseases
treatment
endothelial dysfunction
dysfunction
Prior art date
Application number
SG11201504340YA
Other languages
English (en)
Inventor
Silviu Itescu
Peter Ghosh
Wayne Gregory Kimpton
Simon Reeves Bailey
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of SG11201504340YA publication Critical patent/SG11201504340YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
SG11201504340YA 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation SG11201504340YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Publications (1)

Publication Number Publication Date
SG11201504340YA true SG11201504340YA (en) 2015-07-30

Family

ID=50933585

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504340YA SG11201504340YA (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation
SG10201705061RA SG10201705061RA (en) 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201705061RA SG10201705061RA (en) 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation

Country Status (11)

Country Link
US (2) US20160175360A1 (https=)
EP (2) EP3556850A1 (https=)
JP (5) JP6572130B2 (https=)
KR (3) KR102506612B1 (https=)
CN (2) CN111840329B (https=)
AU (4) AU2013360024B2 (https=)
CA (1) CA2893942C (https=)
ES (1) ES2742035T3 (https=)
IL (1) IL239308A0 (https=)
SG (2) SG11201504340YA (https=)
WO (1) WO2014089623A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5542686B2 (ja) 2007-12-04 2014-07-09 プロテオバイオアクティブズ・ピーティーワイ・リミテッド 前駆細胞の保護およびその分化の調節
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
JPWO2022114111A1 (https=) * 2020-11-27 2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2866468C (en) 2004-09-24 2019-09-03 Mesoblast, Inc. Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
JP2008544957A (ja) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009073616A2 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8124071B2 (en) * 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
JP5542686B2 (ja) * 2007-12-04 2014-07-09 プロテオバイオアクティブズ・ピーティーワイ・リミテッド 前駆細胞の保護およびその分化の調節
JP2011526892A (ja) * 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
EP2350266B1 (en) * 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) * 2010-09-29 2012-04-12 Aidan Research And Consulting, Llc. Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
WO2012162754A1 (en) * 2011-06-03 2012-12-06 Mesoblast, Inc Methods of treating or preventing neurological diseases
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
CA2880808C (en) * 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
JP6431850B2 (ja) * 2013-01-09 2018-11-28 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置

Also Published As

Publication number Publication date
CN105358163B (zh) 2020-09-11
JP2023030116A (ja) 2023-03-07
AU2013360024A1 (en) 2015-07-02
AU2013360024B2 (en) 2019-02-28
AU2019202960A1 (en) 2019-05-16
KR20220029758A (ko) 2022-03-08
AU2021250848A1 (en) 2021-11-04
JP2019214571A (ja) 2019-12-19
CN111840329A (zh) 2020-10-30
KR102506612B1 (ko) 2023-03-06
CN105358163A (zh) 2016-02-24
SG10201705061RA (en) 2017-07-28
HK1210209A1 (en) 2016-04-15
JP2024147655A (ja) 2024-10-16
AU2019202960B2 (en) 2021-07-29
JP7201715B2 (ja) 2023-01-10
ES2742035T3 (es) 2020-02-12
AU2024227208A1 (en) 2024-10-31
KR102217962B1 (ko) 2021-02-22
KR102367981B1 (ko) 2022-02-25
US20160175360A1 (en) 2016-06-23
WO2014089623A1 (en) 2014-06-19
US20240115618A1 (en) 2024-04-11
JP2016504311A (ja) 2016-02-12
EP2931876B1 (en) 2019-05-29
JP2021073240A (ja) 2021-05-13
JP6572130B2 (ja) 2019-09-04
KR20210021104A (ko) 2021-02-24
KR20150093732A (ko) 2015-08-18
CA2893942C (en) 2023-03-28
CA2893942A1 (en) 2014-06-19
EP3556850A1 (en) 2019-10-23
EP2931876A1 (en) 2015-10-21
JP6829288B2 (ja) 2021-02-10
IL239308A0 (en) 2015-07-30
EP2931876A4 (en) 2016-05-25
CN111840329B (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
ZA202100373B (en) Therapeutically active compounds and their methods of use
IL261768B (en) Devices and methods for tissue treatment
IL237070A0 (en) Treatment of vaccine-related diseases and inflammatory diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
ZA201402615B (en) Prevention and treatment of ocular conditions
ZA201405163B (en) Therapeutically active compounds and their methods of use
EP2804850A4 (en) THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
IL233111A0 (en) Preparations for the treatment of inflammation
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
PL2668182T3 (pl) Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
PL2668183T3 (pl) Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
EP2869833A4 (en) TREATMENT OF INFLAMMATORY SKIN DISORDERS
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
ZA201503979B (en) Treatment of diseases involving mucin
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
IL239308A0 (en) Treatment of diseases of endothelial dysfunction and inflammation
IL233080A0 (en) Bisarylsulfonamides used to treat inflammation and cancer
PL2744497T3 (pl) Terapeutyczne połączenia netupitantu i palonosetronu
GB201100651D0 (en) Treatment of inflammation
AU2012900272A0 (en) Treatment and inhibition of corneal erosions
GB201201779D0 (en) Treatment of inflammatory disorders
AU2012901301A0 (en) Treatment of inflammatory and immune disorders